# Alaska Prescription Drug Monitoring Program Summary Prepared for the State Medical Board November 2020



This report contains summary data from the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

#### Notices:

- License integration enhancement has been postponed. The launch was not successful
- We are working with Appriss on being able to issue automatic compliance notifications to providers who directly dispense, letting them know if they miss a day of reporting.
- The RFP for the PDMP contract has been issued; we are in the process of evaluating the proposals and anticipate selecting a vendor by the end of the year.
- The PDMP received two grants: The State Opioid Response (SOR) grant and a partial award of the Bureau of Justice Assistance (BJA) grant.

#### Registration

#### **Portal**

#### Physician Assistants

Number of licensed Physician Assistants: 742

Number of PDMP Physician Assistants registrations: 458

# Physicians (includes Podiatrists and Medical Residents)

Number of licensed Physicians: 4,929

Number of PDMP Physicians registrations: 2380

### AWARXE (PDMP)

Number registered with the PDMP: 3,410 (6% increase from August 2020)

Physician: 3,325

Physician Assistants: 692

Medical Resident with Prescriptive Authority: 59

Podiatrists: 26

Compliance rate: 69% (2% increase since August 2020)

#### Use

Review compliance from June – October 2020: 43.05% (5% increase from August 2020)

#### MME Use (April 2020 – September 2020)

# Physician Assistants

Number of patients treated with over 90 MME: 607 Number of patients treated with over 120 MME: 233

Number of patients treated with dangerous combinations (benzodiazepines and opioids): 507 Number of patients treated with dangerous combinations (benzodiazepines, opioids, carisoprodol): 13

# <u>Physicians</u>

Number of patients treated with over 90 MME: 1,236 (56% decrease from October 2019 – March 2020)

Contact: Lisa Sherrell | PDMP Manager | <u>akpdmp@alaska.gov</u> | 907-269-8404

# Alaska Prescription Drug Monitoring Program Summary Prepared for the State Medical Board November 2020



Number of patients treated with over 120 MME: 518 (52% decrease from October 2019 – March 2020)

Number of patients treated with dangerous combinations (benzodiazepines and opioids): 2,655 (80% decrease from October 2019 – March 2020)

Number of patients treated with dangerous combinations (benzodiazepines, opioids, carisoprodol): 42 (82% decrease from October 2019 – March 2020)

## **Delinquent Reporters**

Providers who directly dispense are required to report daily. We are currently gathering this information on the renewal applications.

#### Recommendations

- Encourage increased reviewing, including the use of delegates
- Provide guidance to licensees on prescribing practices related to the use of dangerous combinations
- Providers should be notified they are not able to prescribe until their registration in AWARXE has been approved.
- Encourage licensees to verify their user roles and specialties in AWARxE to improve the accuracy of reporting.

# PDMP Overview Registration




Figure 1A. Physician includes those registered as Physician, Podiatrist, and Medical Residents with Prescriptive Authority. \*Other includes IHS, VA, and military prescribers and dispensers, admin, coroners, and out-of-state pharmacists.

Contact: Lisa Sherrell | PDMP Manager | akpdmp@alaska.gov | 907-269-8404

# Alaska Prescription Drug Monitoring Program Summary Prepared for the State Medical Board November 2020






Figure 1B. This figure may be underrepresented as there are licensed prescribers inclusive in federal user role categories (IHS Prescriber, VA Prescriber, and Military Prescribers).

#### **MME Use**

June 2020 - October 2020

The CDC recommends that primary care clinicians should reassess evidence of the benefits and risks to the individual when increasing dosage to greater or equal to 50 MME/day and avoid increasing to greater or equal to 90 MME/day when possible due to an increased risk of complications. The CDC also recommends avoiding concurrent benzodiazepine and opioid prescriptions, given the high risk of adverse drug-drug interactions, specifically respiratory depression and death.

# CDC checklist for prescribing opioids -

https://www.commerce.alaska.gov/web/portals/5/pub/PDMP\_OpiodPrescribeCDC\_06.2018.pdf

CDC guidelines for prescribing opioids for chronic pain -

https://www.commerce.alaska.gov/web/portals/5/pub/PDMP OpiodPrescribeCDCPain 2018.10.pdf

	# Providers	# Providers	# Providers	# Providers	Dangerous Combo	
Provider Type	Prescribing at Least Once	Who Reviewed 0 Patients	Prescribing >90MME	Prescribing >120MME	Benzo Opioid	Benzo Opioid Carisoprodol
NUR	499	22% (112)	12% (59)	7% (37)	25% (124)	1% (7)
DEN	311	60% (187)	5% (17)	1% (4)	26% (80)	0
MED	1354	31% (421)	20% (273)	12% (165)	32% (438)	2.6% (35)
PA	294	24% (72)	17% (49)	12% (35)	26% (77)	2% (7)
VET	171	76% (130)	2% (4)	2% (4)	6% (10)	0
ОРТ	2	100% (2)	0	0	0	0

Contact: Lisa Sherrell | PDMP Manager | akpdmp@alaska.gov | 907-269-8404